Literature DB >> 19671741

Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.

Jill K Slack-Davis1, E Daniel Hershey, Dan Theodorescu, Henry F Frierson, J Thomas Parsons.   

Abstract

Increasing evidence indicates that adhesion signaling plays an important role in the tumor microenvironment, contributing to cancer progression, invasion, and metastasis. Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase that regulates adhesion-dependent cell signaling and has been implicated in mediating steps in cancer progression and metastasis in many human cancers, including prostate. We have investigated the role of FAK in the appearance of adenocarcinoma (atypical epithelial hyperplasia of T antigen) and neuroendocrine carcinomas in the transgenic adenocarcinoma of mouse prostate (TRAMP) model using either Cre-mediated recombination to genetically ablate FAK expression or pharmacologic inhibition of FAK activity with the small-molecule inhibitor, PF-562,271. We provide evidence that loss of FAK or its inhibition with PF-562,271 does not alter the progression to adenocarcinoma. However, continued FAK expression (and activity) is essential for the androgen-independent formation of neuroendocrine carcinoma. These data indicate that integrin signaling through FAK is an important component of cancer progression in the TRAMP model and suggest that treatment modalities targeting FAK may be an appropriate strategy for patients with castrate-resistant cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671741      PMCID: PMC2728172          DOI: 10.1158/1535-7163.MCT-09-0262

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  22 in total

1.  Cancer. Respect thy neighbor!

Authors:  Derek C Radisky; Mina J Bissell
Journal:  Science       Date:  2004-02-06       Impact factor: 47.728

2.  Generalized lacZ expression with the ROSA26 Cre reporter strain.

Authors:  P Soriano
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

3.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.

Authors:  X Wu; J Wu; J Huang; W C Powell; J Zhang; R J Matusik; F O Sangiorgi; R E Maxson; H M Sucov; P Roy-Burman
Journal:  Mech Dev       Date:  2001-03       Impact factor: 1.882

4.  Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.

Authors:  G W McLean; K Brown; M I Arbuckle; A W Wyke; T Pikkarainen; E Ruoslahti; M C Frame
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

5.  Expression of focal adhesion kinase in normal and pathologic human prostate tissues.

Authors:  Joshua D Rovin; Henry F Frierson; Wayne Ledinh; J Thomas Parsons; Reid B Adams
Journal:  Prostate       Date:  2002-10-01       Impact factor: 4.104

6.  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Authors:  Yuliya Pylayeva; Kelly M Gillen; William Gerald; Hilary E Beggs; Louis F Reichardt; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

7.  Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Authors:  Mac A Johnson; Philip Iversen; Phillip Schwier; Angela L Corn; George Sandusky; Jeremy Graff; Blake Lee Neubauer
Journal:  Prostate       Date:  2005-03-01       Impact factor: 4.104

8.  Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Authors:  Paula J Kaplan-Lefko; Tsuey-Ming Chen; Michael M Ittmann; Roberto J Barrios; Gustavo E Ayala; Wendy J Huss; Lisette A Maddison; Barbara A Foster; Norman M Greenberg
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

9.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation.

Authors:  Jill K Slack-Davis; Scott T Eblen; Maja Zecevic; Scott A Boerner; Adel Tarcsafalvi; H Bruce Diaz; Mark S Marshall; Michael J Weber; J Thomas Parsons; Andrew D Catling
Journal:  J Cell Biol       Date:  2003-07-21       Impact factor: 10.539

View more
  26 in total

1.  Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Authors:  Colin Walsh; Isabelle Tanjoni; Sean Uryu; Alok Tomar; Ju-Ock Nam; Hong Luo; Angelica Phillips; Neela Patel; Cheni Kwok; Gerald McMahon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

2.  VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

Authors:  Hira Lal Goel; Cheng Chang; Bryan Pursell; Irwin Leav; Stephen Lyle; Hualin Simon Xi; Chung-Cheng Hsieh; Helty Adisetiyo; Pradip Roy-Burman; Ilsa M Coleman; Peter S Nelson; Robert L Vessella; Roger J Davis; Stephen R Plymate; Arthur M Mercurio
Journal:  Cancer Discov       Date:  2012-07-09       Impact factor: 39.397

Review 3.  Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance.

Authors:  Jonathan Cooper; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

4.  Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Authors:  Kristy K Ward; Isabelle Tancioni; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Sean Uryu; Josephine Kim; David Tarin; Dwayne G Stupack; Steven C Plaxe; David D Schlaepfer
Journal:  Clin Exp Metastasis       Date:  2012-12-30       Impact factor: 5.150

5.  Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.

Authors:  Marta Canel; Adam Byron; Andrew H Sims; Jessy Cartier; Hitesh Patel; Margaret C Frame; Valerie G Brunton; Bryan Serrels; Alan Serrels
Journal:  Cancer Res       Date:  2017-08-14       Impact factor: 12.701

6.  IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.

Authors:  Bryan Serrels; Niamh McGivern; Marta Canel; Adam Byron; Sarah C Johnson; Henry J McSorley; Niall Quinn; David Taggart; Alex Von Kreigsheim; Stephen M Anderton; Alan Serrels; Margaret C Frame
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

7.  Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway.

Authors:  Yan Cheng; Xing-Hua Gao; Xian-Jing Li; Qiu-Hua Cao; Dan-Dan Zhao; Jin-Rong Zhou; Hong-Xi Wu; Yun Wang; Lin-Jun You; Hong-Bao Yang; Yun-Long He; Yong-Ren Li; Jin-Song Bian; Qing-Yi Zhu; Lutz Birnbaumer; Yong Yang
Journal:  Oncogene       Date:  2018-03-08       Impact factor: 9.867

Review 8.  Targeting FAK in anticancer combination therapies.

Authors:  John C Dawson; Alan Serrels; Dwayne G Stupack; David D Schlaepfer; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2021-03-17       Impact factor: 60.716

Review 9.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

10.  β4 Integrin signaling induces expansion of prostate tumor progenitors.

Authors:  Toshiaki Yoshioka; Javier Otero; Yu Chen; Young-Mi Kim; Jason A Koutcher; Jaya Satagopan; Victor Reuter; Brett Carver; Elisa de Stanchina; Katsuhiko Enomoto; Norman M Greenberg; Peter T Scardino; Howard I Scher; Charles L Sawyers; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.